Developing new drugs to fight drug-resistant tuberculosis
Official title: Unraveling the spectrum of intrabacterial amide hydrolysis to develop new classes of pyrazinoic acid prodrugs against pyrazinamide resistant Mycobacterium tuberculosis
Funded at Rutgers Biomedical and Health Sciences · NIH-11107921 · Data updated 2026-11-12
This study is looking at how certain bacteria can help create new medicines for tuberculosis, especially for the tough strains that don’t respond to current treatments, so we can find better options for patients dealing with this challenging illness.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project start | June 2, 2025 |
| Project end | May 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $813,373 |
| NIH project number | 1R01AI189899-01 |
| Project ID | NIH-11107921 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with tuberculosis, particularly those with strains resistant to standard treatments.
✕Less likely to help
Patients with non-tuberculosis infections or those who do not have drug-resistant tuberculosis may not benefit from this research.
What this research studies
This research focuses on understanding how certain bacteria can break down specific compounds to create new medications for tuberculosis, particularly for strains resistant to current treatments. The team will investigate the mechanisms by which Mycobacterium tuberculosis can resist existing drugs and explore alternative compounds that can effectively target these resistant strains. By analyzing the bacterial enzymes involved in drug activation, the research aims to design new prodrugs that can be more effective against resistant tuberculosis. This work is crucial for improving treatment options for patients suffering from this global health crisis.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective treatments for tuberculosis, especially for patients with drug-resistant strains.
How similar studies have gone: Previous research has shown promise in developing new treatments for drug-resistant tuberculosis, indicating that this approach could yield significant advancements.
Where this research is happening
-
Rutgers Biomedical and Health Sciences
Newark, United States Active
Researchers
- Principal investigator: Alland, David — Rutgers Biomedical and Health Sciences
- Study coordinator: Alland, David
Related research
Other NIH-funded projects on the same topics.
-
Coronary disease and immune activation in people with HIV and tuberculosis coinfection
This research looks at how having HIV and latent tuberculosis together might raise the risk of heart disease, and what immune changes are involved.
-
Pulmonary rehabilitation to reduce breathing problems after tuberculosis
A program of guided exercise and breathing training to help adults who have recovered from TB breathe better and feel healthier.
-
Pulmonary rehab to reduce breathing troubles after TB
A program of pulmonary rehabilitation is being studied to help adults who have completed TB treatment avoid ongoing lung problems and improve daily breathing.
-
Air pollution and tuberculosis spread in Kampala, Uganda
This project looks at whether dirty air from PM2.5 particles makes tuberculosis more likely to spread within urban slum households in Kampala, Uganda.
-
Air pollution and TB spread in Ugandan urban slums
This project explores whether exposure to air pollution makes tuberculosis more likely to spread within households in a crowded Ugandan slum.
-
Air pollution and TB transmission in Kampala’s urban slums
This project looks at whether air pollution from PM2.5 makes tuberculosis spread more easily from infected people to their neighbors in urban slums of Kampala, Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.